MC2 Therapeutics Announces Approval of Wynzora® Cream in Canada Copenhagen, December 18, 2026 – MC2 Therapeutics, a commercial-stage pharmaceutical company focused on topical therapies in inflammatory skin conditions, today announced that their Canadian partner Knight Therapeutics Inc. (TSX: GUD) has obtained regulatory approval of Wynzora® Cream for the topical treatment of psoriasis vulgaris in adults and […]